Gabriel de Deus Vieira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gabriel de Deus Vieira has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Damasceno
Universidade de Campinas (UNICAMP), Brazil
8 shared publications - Ana Carolina Amaral de Andrade
University of Campinas (UNICAMP)
5 shared publications - Mariana Moreira Soares de Sá
University of Campinas (UNICAMP)
5 shared publications - André Augusto Lemos Vidal de Negreiros
Department of Neurology, Rua Tessalia Vieira de Camargo, Universidade Estadual de Campinas (UNICAMP), 126, Cidade Universitária Zeferino Vaz, Campinas 13083-970, Brazil
4 shared publications Camila Maciel de Sousa
Medical Department, Faculdade São Lucas, Porto Velho, RO, Brazil
4 shared publicationsThaianne da Cunha Alves
Medical Department, Faculdade São Lucas, Porto Velho, RO, Brazil
4 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (05) , 001-003
Procerus sign as a diagnostic clue for progressive supranuclear palsy
The procerus sign is associated with some diseases that initially manifest as atypical parkinsonism, especially progressive supranuclear palsy (PSP). It is described as a vertical contraction of the muscles in the glabellar region. This sign helps to clinically differentiate atypical parkinsonism diseases, especially in the early stages, when many conditions are similar, in terms of clinical presentation and poor response to levodopa. Thus, the procerus sign can be an important clue in the suspicion of PSP.
- 11 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (05) , 001-003
Open AccessProcerus sign as a diagnostic clue for progressive supranuclear palsy
The procerus sign is associated with some diseases that initially manifest as atypical parkinsonism, especially progressive supranuclear palsy (PSP). It is described as a vertical contraction of the muscles in the glabellar region. This sign helps to clinically differentiate atypical parkinsonism diseases, especially in the early stages, when many conditions are similar, in terms of clinical presentation and poor response to levodopa. Thus, the procerus sign can be an important clue in the suspicion of PSP.
- 8 September 2025
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 409, 578752
Cranial neuropathies related to immune checkpoint inhibitors
- 8 September 2025
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 409, 578752
Cranial neuropathies related to immune checkpoint inhibitors
- Open Access
- 15 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (12) , 001-008
Epidemiology and healthcare access in Brazilian multiple sclerosis patients: insights from the BRANDO database
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disorder whose prevalence varies across Brazil (from 15–27 cases per 100 thousand inhabitants), and the absence of an extensive national study limits the understanding of MS epidemiology in a nation as diverse as Brazil. To compare epidemiological data, including healthcare access, among people with MS across four Brazilian regions. Data from 2,974 Brazilian MS patients in the Collaborative Latin American Database for Multiple Sclerosis (BRANDO) were analyzed. We assessed demographic and clinical outcomes, as well as healthcare access, to elucidate regional differences. The cohort was predominantly composed of female patients (72.5%) with MS onset at a mean age of 30.6 years. Regarding the regional differences, there was a lower predominance of female patients (68.7%; p = 0.003) in the Southeast, a higher rate of subjects of mixed ethnicity (p < 0.001) in the Midwest (40.3%) and Northeast (63.7%), higher scores on the Expanded Disability Status Scale (EDSS) in the Northeast (4.0; p < 0.001), a higher prevalence of relapsing-remitting MS (RRMS) in the Southeast and Midwest (87%; p < 0.001), while the Northeast presented (p < 0.001) the highest rates of primary progressive MS (PPMS) and secondary progressive MS (SPMS) (PPMS = 15.8%; SPMS = 18%). The Northeast presented the longest time (5.9 years; p < 0.01) from disease onset until MS diagnosis (range for the other regions = 1.9–3.7 years). And the Midwest showed the shortest time (2.1 years; p < 0.01) from disease onset until first access to disease-modifying therapies (DMTs; range for the other regions = 3.5–5.1 years). The present is the first nationwide epidemiological study on people with MS in Brazil. It underscores regional epidemiological variations and differences in healthcare access, advocating for tailored approaches in MS management and research.
- 15 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (12) , 001-008
Open AccessEpidemiology and healthcare access in Brazilian multiple sclerosis patients: insights from the BRANDO database
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disorder whose prevalence varies across Brazil (from 15–27 cases per 100 thousand inhabitants), and the absence of an extensive national study limits the understanding of MS epidemiology in a nation as diverse as Brazil. To compare epidemiological data, including healthcare access, among people with MS across four Brazilian regions. Data from 2,974 Brazilian MS patients in the Collaborative Latin American Database for Multiple Sclerosis (BRANDO) were analyzed. We assessed demographic and clinical outcomes, as well as healthcare access, to elucidate regional differences. The cohort was predominantly composed of female patients (72.5%) with MS onset at a mean age of 30.6 years. Regarding the regional differences, there was a lower predominance of female patients (68.7%; p = 0.003) in the Southeast, a higher rate of subjects of mixed ethnicity (p < 0.001) in the Midwest (40.3%) and Northeast (63.7%), higher scores on the Expanded Disability Status Scale (EDSS) in the Northeast (4.0; p < 0.001), a higher prevalence of relapsing-remitting MS (RRMS) in the Southeast and Midwest (87%; p < 0.001), while the Northeast presented (p < 0.001) the highest rates of primary progressive MS (PPMS) and secondary progressive MS (SPMS) (PPMS = 15.8%; SPMS = 18%). The Northeast presented the longest time (5.9 years; p < 0.01) from disease onset until MS diagnosis (range for the other regions = 1.9–3.7 years). And the Midwest showed the shortest time (2.1 years; p < 0.01) from disease onset until first access to disease-modifying therapies (DMTs; range for the other regions = 3.5–5.1 years). The present is the first nationwide epidemiological study on people with MS in Brazil. It underscores regional epidemiological variations and differences in healthcare access, advocating for tailored approaches in MS management and research.
- Open Access
- 21 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (09) , 001-008
Anti-pan-neurofascin IgG3: insights about an emerging autoimmune nodoparanodopathy
Neurofascin constitutes a family of cell-surface proteins identified more than 4 decades ago, produced through alternative RNA splicing, with various isoforms expressed in neural tissues. With the emergence of chronic inflammatory demyelinating polyneuropathy (CIDP) subtypes characterized by distinct pathological mechanisms, antineurofascin antibody-mediated neuropathies have gained attention and are now categorized as autoimmune nodoparanodopathies. Among these, the anti-pan-neurofascin immunoglobulin G3 (IgG3) subtype presents a particularly severe and diagnostically-challenging phenotype, marked by a fulminant clinical course, diverse symptomatology, and high rates of morbidity and mortality. Despite its clinical relevance, to date, no comprehensive review has focused specifically on this manifestation, highlighting a significant gap in the literature. To address this, we herein review the seven reported cases and explore the proposed pathophysiological mechanism involving the destruction of the node of Ranvier via hyperactivation of membrane attack complex (MAC) formation. Additionally, we examine emerging evidence supporting the use of eculizumab as a potential therapeutic option, alongside other treatment strategies. Finally, we discuss the role of standardized antibody assays, serological analyses, and neurophysiological studies in improving diagnostic accuracy.
- 21 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (09) , 001-008
Open AccessAnti-pan-neurofascin IgG3: insights about an emerging autoimmune nodoparanodopathy
Neurofascin constitutes a family of cell-surface proteins identified more than 4 decades ago, produced through alternative RNA splicing, with various isoforms expressed in neural tissues. With the emergence of chronic inflammatory demyelinating polyneuropathy (CIDP) subtypes characterized by distinct pathological mechanisms, antineurofascin antibody-mediated neuropathies have gained attention and are now categorized as autoimmune nodoparanodopathies. Among these, the anti-pan-neurofascin immunoglobulin G3 (IgG3) subtype presents a particularly severe and diagnostically-challenging phenotype, marked by a fulminant clinical course, diverse symptomatology, and high rates of morbidity and mortality. Despite its clinical relevance, to date, no comprehensive review has focused specifically on this manifestation, highlighting a significant gap in the literature. To address this, we herein review the seven reported cases and explore the proposed pathophysiological mechanism involving the destruction of the node of Ranvier via hyperactivation of membrane attack complex (MAC) formation. Additionally, we examine emerging evidence supporting the use of eculizumab as a potential therapeutic option, alongside other treatment strategies. Finally, we discuss the role of standardized antibody assays, serological analyses, and neurophysiological studies in improving diagnostic accuracy.
- 20 February 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 95, 106311
Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders
- 20 February 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 95, 106311
Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders
- Open Access
- 24 October 2024
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 32 (2) , 75-77
Spectrum of Neuroimmunological Manifestations of Dengue Fever
- 24 October 2024
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 32 (2) , 75-77
Open AccessSpectrum of Neuroimmunological Manifestations of Dengue Fever
- 8 September 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 91, 105867
Association between paramagnetic rim lesions with cognitive impairment in pediatric multiple sclerosis
- 8 September 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 91, 105867
Association between paramagnetic rim lesions with cognitive impairment in pediatric multiple sclerosis
- Open Access
- 1 August 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (S 01) , S1-S52
Diffusion-tensor imaging findings related to disability and quality of life in multiple sclerosis: a 12-year follow-up
Address for correspondence: Gabriel Vieira (email: gabrieldedeusvieira@gmail.com). Abstract Background: Diffusion-tensor imaging (DTI) is an advanced magnetic resonance imaging (MRI) technique that provides information on microscopic structural damage in white-matter tracts, related to demyelinating and axonal damage. Objective: To evaluate 12-year longitudinal metrics in functional tests and DTI parameters. Methods: We selected 30 patients from a previous cohort, and a new assessment was performed 12 years after (time point 2, tp2) the baseline assessment. The clinical variables evaluated were the EDSS, 9HPT, T25FW, and SDMT. The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) was applied to all patients. We also evaluated the quality-of-life parameters. The DTI images were acquired on a 3-T device and analyzed using MRtrix3 (https://www.mrtrix.org). We selected the following tracts and fascicles: uncinate (UnF), cingulate (CgF), inferior fronto-occipital (IFOF), corpus callosum (CC), corticospinal tract (CST), and the fornix (FxF). Group comparisons were performed with the paired t-test. A multivariable linear regression was also performed. Results: Regarding the functional and cognitive tests, those that showed a significant variation between baseline and tp2 were the EDSS (t (29) = -2.715; p < 0.01), 9HPT (t (40) = -2.202; p < 0.05), and PASAT z-score (t (40) = -2.829; p < 0.01). During baseline, no clinical variables were entered into the equation for DTI analyses. During tp2, the IFOF-FA delta was related to the T25FW (R2 = 0.701; β = -0.992; p < 0.001), the MCC-FA delta was related to fatigue (R2 = 0.289; β = -0.699; p = 0.02), and the UnF-FA delta (R2 = 0.171; β = -0,423; p = 0.009) and the UnF-RD delta (R2 = 0.218; β = -0.466; p = 0.006) were related to depression. Conclusion: In the 12 years of follow-up, damage to the IFOF-FA was a predictor of changes in the T25FWT, in addition to UnF-FA being related to depression. Article published online: 02 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 1 August 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (S 01) , S1-S52
Open AccessDiffusion-tensor imaging findings related to disability and quality of life in multiple sclerosis: a 12-year follow-up
Address for correspondence: Gabriel Vieira (email: gabrieldedeusvieira@gmail.com). Abstract Background: Diffusion-tensor imaging (DTI) is an advanced magnetic resonance imaging (MRI) technique that provides information on microscopic structural damage in white-matter tracts, related to demyelinating and axonal damage. Objective: To evaluate 12-year longitudinal metrics in functional tests and DTI parameters. Methods: We selected 30 patients from a previous cohort, and a new assessment was performed 12 years after (time point 2, tp2) the baseline assessment. The clinical variables evaluated were the EDSS, 9HPT, T25FW, and SDMT. The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) was applied to all patients. We also evaluated the quality-of-life parameters. The DTI images were acquired on a 3-T device and analyzed using MRtrix3 (https://www.mrtrix.org). We selected the following tracts and fascicles: uncinate (UnF), cingulate (CgF), inferior fronto-occipital (IFOF), corpus callosum (CC), corticospinal tract (CST), and the fornix (FxF). Group comparisons were performed with the paired t-test. A multivariable linear regression was also performed. Results: Regarding the functional and cognitive tests, those that showed a significant variation between baseline and tp2 were the EDSS (t (29) = -2.715; p < 0.01), 9HPT (t (40) = -2.202; p < 0.05), and PASAT z-score (t (40) = -2.829; p < 0.01). During baseline, no clinical variables were entered into the equation for DTI analyses. During tp2, the IFOF-FA delta was related to the T25FW (R2 = 0.701; β = -0.992; p < 0.001), the MCC-FA delta was related to fatigue (R2 = 0.289; β = -0.699; p = 0.02), and the UnF-FA delta (R2 = 0.171; β = -0,423; p = 0.009) and the UnF-RD delta (R2 = 0.218; β = -0.466; p = 0.006) were related to depression. Conclusion: In the 12 years of follow-up, damage to the IFOF-FA was a predictor of changes in the T25FWT, in addition to UnF-FA being related to depression. Article published online: 02 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 26 April 2024
- Published by Springer Nature in Neuroradiology
- Vol. 66 (7) , 1199-1202
Enlargement of the choroid plexus in pediatric multiple sclerosis
Some studies have suggested an inflammatory role of the choroid plexus (CP) in the pathophysiology of multiple sclerosis (MS), but mainly in adult patients. We aimed to evaluate clinical and MRI parameters in patients with pediatric-onset multiple sclerosis (POMS). We included 10 patients with POMS and 16 healthy controls (HC), evaluating clinical and neuroimaging variables (cerebral cortex, CP, deep gray matter structures, and demyelinating lesions). Most patients were girls (80%), with a mean age of 15.3 years. POMS individuals had a higher CP volume (p = 0.012) and lower thalamic volume (p = 0.038) compared to HC. This study shows an enlargement of the CP and lower thalamic volume in POMS patients compared to HC.
- 26 April 2024
- Published by Springer Nature in Neuroradiology
- Vol. 66 (7) , 1199-1202
Enlargement of the choroid plexus in pediatric multiple sclerosis
Some studies have suggested an inflammatory role of the choroid plexus (CP) in the pathophysiology of multiple sclerosis (MS), but mainly in adult patients. We aimed to evaluate clinical and MRI parameters in patients with pediatric-onset multiple sclerosis (POMS). We included 10 patients with POMS and 16 healthy controls (HC), evaluating clinical and neuroimaging variables (cerebral cortex, CP, deep gray matter structures, and demyelinating lesions). Most patients were girls (80%), with a mean age of 15.3 years. POMS individuals had a higher CP volume (p = 0.012) and lower thalamic volume (p = 0.038) compared to HC. This study shows an enlargement of the CP and lower thalamic volume in POMS patients compared to HC.
- Open Access
- 30 January 2024
- Published by Scientific Archives in Journal of Experimental Neurology
- Vol. 5 (1) , 40-41
Definition and Characteristics of Multiple Sclerosis with Predominant Cognitive Presentation
We recently reported a longitudinal MRI and cognitive follow-up of a patient with multiple sclerosis with predominant cognitive presentation (MSCP), showing the evolution of the disease and the difficulty in its early diagnosis.
- 30 January 2024
- Published by Scientific Archives in Journal of Experimental Neurology
- Vol. 5 (1) , 40-41
Open AccessDefinition and Characteristics of Multiple Sclerosis with Predominant Cognitive Presentation
We recently reported a longitudinal MRI and cognitive follow-up of a patient with multiple sclerosis with predominant cognitive presentation (MSCP), showing the evolution of the disease and the difficulty in its early diagnosis.